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Abstract: Modulation of the immune system for therapeutic ends has a long history, stretching back to Edward Jenner’s use of 
  cowpox to induce immunity to smallpox in 1796. Since then, immunotherapy, in the form of prophylactic and therapeutic vaccines, has 
enabled doctors to treat and prevent a variety of infectious diseases, including cholera, poliomyelitis, diphtheria, measles and mumps. 
­ Immunotherapy­is­now­increasingly­being­applied­to­oncology.­Cancer­immunotherapy­attempts­to­harness­the­power­and­specificity­of­
the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is 
capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune 
responses. Thus, the challenge for cancer immunotherapy is to apply advances in cellular and molecular immunology and develop 
  strategies that effectively and safely augment antitumor responses.
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Introduction
Advances  in  cellular  and  molecular  immunology 
over the past three decades have provided   enormous 
insights  into  the  nature  and  consequences  of 
  interactions between tumors and immune cells. This 
knowledge continues to lead to strategies by which 
the immune system might be harnessed for therapy of 
established malignancies.
Cells  of  the  innate  immune  system  respond  to 
“danger” signals, which can be provided by   growing 
tumors as a consequence of the genotoxic stress of 
cell transformation and disruption of the   surrounding 
microenvironment. Under ideal   conditions, these sig-
nals­induce­inflammation,­activate­innate­­ effector­cells­
with  antitumor  activity,  and    stimulate    professional 
antigen-presenting  cells  (APCs),    particularly  den-
dritic cells (DCs), to engulf tumor-derived antigens 
and migrate to draining lymph nodes to trigger an 
  adaptive response by T and B lymphocytes. Despite 
this    well-orchestrated    surveillance  operation,  the 
  presence  of  a  tumor  indicates  that  the  develop-
ing   cancer was able to avoid detection or to escape 
or  overwhelm  the  immune  response.  Progressing 
tumors often exhibit strategies that promote evasion 
from  immune  recognition.1  This  includes  physical 
exclusion  of  immune  cells  from  tumor  sites,  poor 
immunogenicity due to reduced expression of major 
histocompatability complex (MHC) or co-stimulatory 
proteins, and disruption of natural killer (NK) and 
natural killer T (NKT) cell recognition.2 Additionally, 
some­tumors­prevent­triggering­of­an­inflammatory­
response by secreting proteins, such as interleukin 
(IL)-10 or vascular endothelial growth factor (VEGF) 
that interfere with DC activation and differentiation3 
or­by­blocking­the­production­of­pro-inflammatory­
molecules  by  increasing  expression  of  the  STAT3 
protein.4 Even if a response is induced, tumor cells 
may escape elimination by losing targeted antigens, 
rendering  tumor-reactive  T-cells  anergic,  inducing 
regulatory­T-cells,­or­specifically­deleting­respond-
ing T-cells.5,6 Thus, there is often a cat and mouse 
game with the immune system exerting pressure to 
eliminate the tumor, and the tumor cells evading the 
immune response; the eventual tumor that develops 
reflects­ “­ immunoediting”­ with­ ­ selection­ of­ poorly­
immunogenic  and/or  immune-resistant  malignant 
cells.7 Despite these obstacles, modern   immune-based 
therapies  continue  to  show  increased  potential  for 
treating malignant diseases.
Innate cells as Initiators of the 
Adaptive Immune Response
One­of­the­first­strategies­to­enhance­immune­responses­
to cancer was the administration of   adjuvants directly 
into­solid­tumors­to­stimulate­inflammation­and­recruit­
immune effector cells. This approach is still commonly 
used­for­treating­superficial­bladder­­ carcinomas­and­has­
been used to treat melanoma and neurological tumors. 
It is now known that many of these adjuvants contain 
bacterial products, such as   lipopolysaccharide (LPS) 
or CpG-containing oligo-deoxynucleotides   recognized 
by toll-like receptors (TLRs) on innate immune cells. 
This­ leads­ to­ the­ production­ of­ ­ pro-inflammatory­
cytokines  and  facilitating  productive  interactions 
between the innate and adaptive immune responses.8 
Although many tumors render this strategy ineffective 
by producing   proteins, such as transforming growth 
factor (TGF)-β to   prevent   activation of the immune 
response,9 more recent reports describes CD8+ help for 
innate antitumor immunity10 and cooperative action of 
CD8 T lymphocytes and natural killer cells   controlling 
tumor  growth  under  conditions  of  restricted  T-cell 
receptor diversity.11
Several  papers  have  also  described  the  role  of 
  adaptive immunity not only in suppressing but also 
activating innate immune responses in other   diseases. 
These  include  the  role  of  CD8+ T  cells    mediating 
  antibacterial immunity via CCL3   activation of TNF/
ROI+  phagocytes12  or  contributing  to    macrophage 
recruitment­ and­ adipose­ tissue­ inflammation­
in    obesity.13  Furthermore,  studies    investigating 
c  ooperation between innate and adoptive   immunity 
cooperating­ flexibly­ to­ maintain­ host-­ microbiota­
mutualism14  or  dampening  of  innate  immune 
responses by T cells through inhibition of NLRP1 and 
NLRP3­inflammasomes,15 have also been described.
cellular Immunotherapy
T-cells express clonally distributed antigen   receptors 
that in the context of MHC proteins can recognize either 
unique tumor antigens, those evolving from mutations 
or  viral  oncogenesis  or  self-antigens,  those  derived 
from over expression of proteins or aberrant e  xpression 
of  antigens  that  are  normally    developmentally  or Cancer immunotherapy
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tissue-restricted. To mediate   antitumor activity, T-cells 
must­ first­ be­ activated­ by­ bone­ ­ marrow—derived­
APCs that present tumor   antigens and provide   essential 
  co-stimulatory signals,16 migrate and gain access to the 
tumor microenvironment, and overcome   obstacles to 
effective  triggering  posed  by  the  tumor. Activation 
results in the production of cytokines, such as inter-
feron (IFN) and tumor necrosis factor (TNF) that can 
arrest proliferation of malignant cells and prevent the 
angiogenesis  necessary  for  tumor  growth,  and  also 
lysis of tumor cells mediated by perforin and/or Fas. 
Consequently,  efforts  have  focused  on  identifying 
tumor  antigens,  providing  the  antigens  in  immuno-
genic formats to induce responses, manipulating T-cell 
responses to increase the number of reactive cells and 
augmenting effector functions (Table 1).
Active and passive Immunotherapy
A  number  of  immunologic  interventions,  which 
can be divided into both passive and active, can be 
directed  against  tumor  cells.17  In  passive  cellular 
­ immunotherapy,­ specific­ effector­ cells­ are­ directly­
infused and are not induced or expanded within the 
patient.  Lymphokine-activated  killer  (LAK)  cells 
are produced from the patient’s endogenous T cells, 
which are extracted and grown in a cell culture   system 
by exposing them to interlukin-2 (IL-2). The prolif-
erated LAK cells are then returned to the patient’s 
bloodstream. Clinical trials of LAK cells in humans 
are­ongoing.­Tumor-infiltrating­lymphocytes­(TILs)­
may have greater tumoricidal activity than LAK cells. 
These cells are grown in culture in a manner similar 
to LAK cells. However, the progenitor cells consist 
of T cells that are isolated from resected tumor tissue. 
This process theoretically provides a line of T cells 
that­has­greater­tumor­specificity­than­those­obtained­
from the bloodstream. Concomitant use of interferon 
enhances the expression of major histocompatability 
complex (MHC) antigens and tumor-associated anti-
gens (TAAs) on tumor cells, thereby augmenting the 
killing of tumor cells by the infused effector cells.
Active immunotherapy
Inducing  cellular  immunity  (involving  cytotoxic  T 
cells)  in  a  host  that  failed  to  spontaneously  develop 
an  effective  response  generally  involves  methods  to 
enhance   presentation of tumor antigens to host   effector 
cells.­ Cellular­ immunity­ can­ be­ induced­ to­ specific,­
very­well-defined­antigens.­Several­­ techniques­can­be­
used to stimulate a host response; these may involve 
giving peptides, DNA, or tumor cells (from the host 
or  another  patient).    Peptides  and  DNA  are  often 
given  using    antigen-  presenting  cells  (dendritic  cells). 
These  dendritic  cells  can  also  be    genetically  modi-
fied­to­secrete­­ additional­immune-response­­ stimulants­
(e.g. granulocyte-  macrophage   colony-stimulating factor 
(GM-CSF) that will be discussed in more detail later.
Nonspecific immunotherapy
Interferons (IFN-α, -β, -γ) are glycoproteins that have 
antitumor and antiviral activity. Depending on dose, 
interferons may either enhance or decrease   cellular and 
humoral immune functions. Interferons also inhibit 
division and certain synthetic processes in a variety 
of cells. Clinical trials have indicated that interferons 
have antitumor activity in various   cancers, including 
hairy  cell  leukemia,  chronic  myelocytic  leukemia, 
AIDS-associated  Kaposi’s  sarcoma,    non-Hodgkin 
lymphoma,  multiple  myeloma,  and  ovarian  carci-
noma.­ However,­ interferons­ may­ have­ significant­
adverse effects, such as fever, malaise, leukopenia, 
alopecia, and myalgias.
Adoptive Immunotherapy
High-dose  chemo-radiotherapy  followed  by  rescue 
from the resulting ablation of normal bone marrow 
with  an  allogeneic  hematopoietic  stem  cell  trans-
plant (HSCT) has become standard therapy for many 
hematologic  malignancies.  One  problem  with  this 
treatment is graft-versus-host disease (GVHD), due 
to allogeneic donor-derived T-cells injuring the “for-
eign” normal tissues of the host. However, malignant 
cells that survive chemoradiotherapy are also of host 
origin, and patients who develop GVHD have lower 
relapse rates from an associated graft-versus-tumor 
(GVT) effect. T-cells mediate this antitumor activ-
ity,­as­affirmed­by­the­complete­responses­sometimes­
observed in patients who receive infusions of donor 
T-cells to treat relapse after HSCT and in recipients 
of a newly developed non-myeloablative allogeneic 
HSCT regimen in whom, because of the absence of 
high-dose  chemoradiotherapy,  all  antitumor  effects 
must result from GVT effects.18 However, the GVT 
activity with these regimens is often associated with Joseph Murphy
70  Clinical Medicine Insights: Oncology 2010:4
severe and life-threatening GVHD. Ongoing efforts to 
define­antigenic­targets­with­limited­tissue­­ distribution,­
permitting donor lymphocytes to   preferentially tar-
get malignant cells and not critical normal tissues, 
  coupled with methods to generate and/or select T-cells 
with­such­specificities,­should­provide­a­much-needed­
refinement­to­this­approach.19
An alternative to using allogeneic T-cells to   mediate 
antitumor responses has been to isolate autologous 
tumor-reactive T-cells, expand the cells in vitro, and 
then re-infuse the cells back into the patient. This 
approach circumvents many of the obstacles to gen-
erating an adequate response in vivo, as the nature of 
the APCs and components of the microenvironment 
can be more precisely controlled in vitro. However, 
this strategy has required the recent development of 
methods  to  extensively  manipulate T-cells  in  vitro 
with­retention­of­specificity­and­function,­such­that­
after infusion the cells will survive and migrate to and 
eliminate tumor cells.
Initial­ therapies­ used­ tumor-infiltrating­ lympho-
cytes as an enriched source of tumor-reactive cells, 
but such cells can also usually be obtained from cir-
culating blood lymphocytes. Although optimal meth-
ods­ for­ stimulating­ and­ expanding­ antigen-specific­
T-cells in vitro­are­still­being­defined,­in­general,­DCs­
  presenting the antigen are used to initially trigger reac-
tive T-cells, which can then be selected and stimulated 
with antibodies to CD3. Supplemental cytokines are 
provided during cell culture to support lymphocyte 
proliferation, survival, and   differentiation. With this 
approach, it has been possible to expand tumor-  reactive 
T-cells to enormous numbers in vitro, infuse billions 
of­specific­cells­without­overt­toxicity­to­achieve­in 
vivo   frequencies beyond that attainable with current 
vaccine regimens. However, despite the high in vivo 
frequencies of tumor-reactive effector cells achieved, 
only  a  fraction  of  patients  respond,  indicating  the 
existence of additional hurdles. One essential require-
ment is that infused cells must persist to mediate an 
effective response. Analogous adoptive therapy trials 
for  cytomegalovirus  and  Epstein-Barr  virus  infec-
tion in immuno-suppressed hosts have demonstrated 
increased in vivo proliferation and   persistence of CD8 
effector­T-cells­in­the­presence­of­specific­CD4­helper­
T-cells.20 Such CD4 T-cells likely provide many ben-
eficial­functions,­including­cytokine­production­and­
APC activation, which can improve the quality and 
quantity of the CD8 responses, as well as direct   effector 
activities against infected or tumor targets. However, 
unlike  viral  responses  that  induce  robust  CD4  and 
CD8  responses,  identifying  and    characterizing  the 
specificity­of­tumor-reactive­CD4­T-cells­has­proven­
considerably­more­difficult­than­with­CD8­responses.­
Additionally, obstacles to safely maintaining a CD4 
response reactive with a   potentially normal protein 
remain  to  be  elucidated.  Consequently,  CD4  help 
is  largely  provided  to    transferred    tumor-  reactive 
CD8  cells  in  the  form  of  surrogate    exogenous 
  cytokines. The largest experience is with IL-2, which 
prolongs persistence and enhances the antitumor activ-
ity of transferred CD8 cells.21   Alternative cytokines 
such as IL-15, IL-7, and IL-21, as well as activation 
of APCs with   antibodies to CD40, are currently being 
evaluated in preclinical studies.
Although polyclonal infusion has shown promis-
ing outcomes in some tumor models that are suscep-
tible to antigenic drift or loss of immune selection,22,23 
the infusion of T-cell clones represents an appealing 
refinement­of­adoptive­therapy­because­the­specificity,­
avidity, and effector functions of infused cells can be 
precisely­defined.­This­facilitates­subsequent­analy-
sis­of­requirements­for­efficacy,­basis­for­toxicity,­and­
rational design of improved therapies. The transfer of 
antigen-specific­CD8­T-cell­clones­has­been­shown­
to be effective for prevention of viral infections and 
treatment of malignant disease.25 Such studies have 
also formally demonstrated that low, nontoxic doses 
of­IL-2­are­sufficient­to­promote­the­in vivo persis-
tence and antitumor activity of CD8 T-cells.
cancer Vaccines
Therapeutic cancer vaccines target the cellular arm of 
the immune system to initiate a cytotoxic T-  lymphocyte 
response  against  tumor-associated    antigens.24  The 
development  of  human  therapeutic  cancer  vaccines 
has come a long way since the discovery of major his-
tocompatability complex (MHC) restricted tumor anti-
gens in the eighties. The simplest model of immune 
cell-mediated­antigen-specific­tumor­­ rejection­­ consists­
of­three­elements:­appropriate­antigen,­specific­for­the­
tumor,­efficient­antigen­­ presentation­and­the­genera-
tion of potent effector cells. Moreover, the critical time 
when immune responses against the tumor are most 
important should also be determined. While   eliminating 
some early transformed cells may be ongoing in an Cancer immunotherapy
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  asymptomatic way as part of the   immunosurveillance, 
if early elimination failed,   equilibrium between small 
tumors and the immune system may be established. If 
the immune system is unable to maintain this equilib-
rium, tumors may escape and it is this last phase when 
they become symptomatic. Therapeutic cancer vaccines 
are applied in this last phase in order to reverse the lack 
of tumor control by the immune system. In addition to 
the increasing knowledge about how to optimize the 
elements of anti-tumor immunity in order to generate 
clinically relevant responses, there is an ever-increas-
ing list of immune evasion mechanisms impeding the 
efforts of cancer vaccines. This indicates that the ele-
ments necessary for immune-mediated tumor rejection 
need to be optimized.25
Potential  tumor  associated  antigens  (TAAs)  can 
be­identified­by­the­elution­of­peptides­from­MHC­
  molecules  on  tumor  cells,26  or  with  proteomic 
approaches such as 2-dimensional gel   electrophoresis, 
MALDI-MS  and  SELDI-MS  (matrix-assisted  or 
  surface  enhanced  laser-desorption  ionization  mass 
spectrometry).27 Serological analysis of   recombinant 
cDNA  expression  libraries  (SEREX)  is  another 
widely used method; it utilizes sera of cancer patients 
to detect over expressed antigens from tumor cDNA 
libraries.28 Furthermore, several RNA-based methods 
have also gained importance; transcriptome   analysis 
that  include  DNA  microarrays,29  serial  analysis  of 
gene    expression  (SAGE),30  comparative  genomic 
  hybridization (CGH)31 and massively   parallel   signature 
  sequencing  (MPSS).32  These    methods    provide  an 
enormous amount of information and require   complex 
computer-aided analysis and interpretation of the data, 
referred­to­as­gene­expression­profiling.­This­is­neces-
sary­in­order­to­find­gene­expression­patterns­and­to­
distinguish them from noise.33
Following  promising  in  vitro    immunogenicity 
studies,34 multicentre vaccine trials have been orga-
nized  with  the  sponsorship  of  the  Cancer Vaccine 
Collaborative (NCI and Ludwig Institute for Cancer 
Research). These trials have provided some informa-
tion about the optimum route of administration, type 
of vaccine, type of adjuvant, endpoints, etc.35 When 
testing  the  immunogenicity  of  candidate  antigens 
and­defining­epitopes,­it­should­be­remembered­that­
T-cells  with  high  avidity  for  self  antigen  undergo 
negative  selection  during T-cell  development,  thus 
the new TAAs may only generate T-cell responses of 
intermediate­or­low­affinity.­Furthermore,­the­wide­
range of restriction elements in the human population 
means that due to the combination of tolerance and 
immunodominance, potentially ideal TAAs will not 
be equally immunogenic in all patients. Antigen loss 
may also occur during tumor progression, as TAAs 
which are not necessary for the maintenance of the 
transformed  phenotype  may  be  deleted  and  tumor 
cells in advanced disease may express antigens dif-
ferent from those in early stages.36
Dendritic cells
DCs  are  the  main  antigen  presenting  cells  in  the 
body37 and their generation for anti-tumor   immunity 
has­been­the­focus­of­a­vast­array­of­scientific­and­
  clinical  studies.38  Immature  DC  (iDC)  patrol  the 
peripheral  tissues,  sampling  antigen  from  the 
  environment.   Following their activation, DC undergo 
a maturation process that involves the upregulation of 
T cell   co-stimulatory molecules, (e.g. CD80, CD86), 
increased cytokine secretion, a transient increase in 
phagocytosis   followed by reduced antigen uptake and 
expression  of  migratory  molecules  such  as  CCR7. 
These  changes  equip  mature  DC  (mDC)  to  prime 
naïve T cells in the lymph nodes, in contrast to iDC 
that induce T cell tolerance to antigen.39
The  ability  of  DCs  to  present  protein  tumor 
  antigens (T-Ags) to CD4+ and CD8+ T-cells is pivotal 
to the success of therapeutic cancer vaccines. DC’s 
specialized capacity to cross-present exogenous Ags 
onto major histocompatability (MHC) class I mol-
ecules­for­the­generation­of­T-Ag-specific­cytotoxic­
T lymphocytes (CTLs) has made these cells the focal 
point of vaccine-based immunotherapy of cancer.
DC can be loaded exogenously with TAA using 
whole cell populations or short peptides correspond-
ing­to­epitopes­from­specific­TAA.­Whilst­the­use­of­
DC pulsed with short peptides can yield information 
on  immune  activation  following  therapy,  they  are 
not ideal therapeutic agents for a number of reasons. 
The­most­obvious­reason­is­the­use­of­specific­TAA­
depends­on­the­identification­of­relevant­TAA­and­not­
all­cancers­have­well­defined­TAA.­Moreover,­TAA­
expression within a tumor can be very heterogeneous40 
thus­priming­CTL­specific­for­defined­TAA­peptides­
may  encourage  the  outgrowth  of  non-expressing 
clones, leading to immune evasion. Furthermore, both 
MHC-1­and­MHC-II­epitopes­are­required­for­efficient­Joseph Murphy
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T cell priming. While a number of MHC-1 restricted 
peptides­have­been­identified,­fewer­MHC-II­epitopes­
are known. Synthetic long peptides, comprising both 
MHC-I and MHC-II epitopes, which require process-
ing by DC before presentation, can overcome some 
of the limitations of small peptides, as they lead to 
extended epitope presentation. An alternative to puls-
ing with peptide epitopes is to load DC with whole 
tumor cell preparations in the form of lysates, whole 
dead cells or by fusing DC with tumor cells.41 Both 
allogeneic and autologous tumor material has been 
used to load DC with clinical trials carried out using 
preparations using both types.42
Genetic­ modification­ of­ DC,­ using­ recombinant­
DNA viruses encoding TAA, has been demonstrated 
by several groups, and can enhance T cell priming 
potential via antigen presentation. DC transduced to 
express the model tumor antigen β-galactisidase, using 
a recombinant adenoviral vector, were able to   generate 
antigen-specific­CTL­responses.43 A phase I/II trial 
using­genetically­modified­DC,­showed­that­autolo-
gous­DC­could­be­transduced­with­high­efficiency­
using a replication-defective adenovirus expressing 
full length melanoma-associated antigen recognized 
by  T-cells  (MART-1),  and  that  the  DC  processed 
and presented the antigen for at least 10 days. Evi-
dence­of­MART-1­specific­CD4+ and CD8+ responses 
were  found  in  around  50%  of  patients  following 
vaccination.44
In addition to loading DC with antigen, genetic 
approaches have been used to further optimize the 
maturation state of DC, for example, DC transfected 
with GM-CSF demonstrated increased antigen pre-
sentation and better migratory capacity, which trans-
lated into enhanced immune priming in vivo.45 Other 
approaches include genetically modifying DC using 
adenoviral or retroviral vectors to directly express TH1 
cytokine IL-12,46 an adenovirus encoding CD40 L47 
and  modifying  DC  to  express  co-stimulatory  mol-
ecules CD40 L, CD70 and TLR4 called “TriMix”,48 
and heat shock protein.49 Furthermore, vaccines cou-
pled­to­TLR­ligands­lead­to­efficient­CTl­activation­
by endogenous DC50 and the use of oncolytic viruses 
also looks particularly promising.51
Treg cells
Since  their  discovery  in  the  1960s  as  suppressive 
T cells, Tregs have been extensively studied in a wide 
range of both physiological and pathological   conditions 
in man.52 Treg suppress T-cell responses and provide 
another mechanism compromising the   development 
of effective tumor immunity.53 These cells are usu-
ally CD4+ and are distinguishable   phenotypically by 
expression of CD25 (the chain of the IL-2 receptor 
required­ for­ high­ affinity­ binding),­ high­ levels­ of­
CTLA-4,  the  glucocorticoid-induced  TNF-related 
receptor (GITR), and the forkhead transcription   factor 
Foxp3.­Expression­of­TNFR2­defines­a­maximally­
suppressive  subset  of  mouse  CD4+CD25+FoxP3+ 
Treg54 and co-expression of TNFR2 and CD25 iden-
tifies­more­of­the­functional­CD4+FoxP3+ regulatory 
Treg cells in peripheral human blood.55
Treg cells can arise in response to persistent   antigen 
stimulation­ in­ the­ absence­ of­ inflammatory­ signals,­
particularly in the presence of TGF-ß, and have been 
detected in increased frequency in some cancer patients. 
Furthermore, tumor-induced   expansion of regulatory 
T  cells  by  conversion  of  CD4+CD25+  lymphocytes 
is   thymus and proliferation independent.56 Thymosin 
alpha1 is a peptide with a multitude of effects in the 
organism­both­from­its­direct­influence­on­the­cells,­
as well as modulation of the immune system.57 When 
administered in vivo it strengthens the immune reaction 
in a whole variety of animal models and its optimal 
reaction occurs in coordination with other agents.58
Inhibiting  Treg  cell  function  in  patients  with 
  cancer is an essential step if new therapies, especially 
immunotherapies, are to be clinically successful. Ini-
tial studies have indicated that depleting Treg cells 
from cancer patients might be a valid approach; more 
recent preliminary data has raised the hypothesis that 
functionally inactivating Treg cells might be a better 
alternative. Studies in murine tumor models targeting 
all CD25+ T-cells for depletion have appeared promis-
ing.59 However, activated effector CD8 and CD4 T-cells 
also express CD25, and depletion of these cells during 
the acute phase of the antitumor T-cell response may 
severely limit the application of this approach. The 
availability of the anti-CD25   monoclonal antibody, 
PC61, has enabled the effects of Treg cell depletion 
to be tested in murine models.60­Despite­some­effi-
cacy, intrinsic limitations apply when PC61 is used to 
treat established tumors as time course experiments 
have­reported­that­its­efficacy­is­lost­as­tumors­prog-
ress.61 Other monoclonal antibodies to human CD25 
that are available for   clinical use, such as daclizumab, Cancer immunotherapy
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block IL-2 and receptor interactions are used to treat 
  hematologic malignancies.62 However, to date, most 
studies in humans have used the immunotoxin denile-
ukin­difitox­(Ontak),­a­fusion­protein­between­the­IL-2­
and diphtheria toxin, to selectively kill lymphocytes 
expressing the IL-2 receptor. The in vivo anti-tumor 
efficacy­is­still­under­preclinical­and­clinical­investi-
gation with discrepant results reported so far.
Another­approach­is­to­inhibit­tumor-specific­Treg­
cell expansion. This could be achieved by inhibiting 
the indoleamine 2, 3-dioxygenase (IDO) pathway. Pre-
clinical­data­confirm­that­the­administration­of­an­IDO­
inhibitor­significantly­decreases­the­rate­of­peripheral­
conversion and dramatically impairs tumor growth.63 
Another possible target is transformed growth factor 
(TGF), involved in both proliferation and conversion 
of Treg cells in tumor bearers. Genetically engineered 
mice express a dominant negative form of the TGF 
receptor on lymphocytes show reduced, if not absent, 
growth of several transplanted tumors.64 Moreover, 
CTLA-4 blockade or GITR triggering has been shown 
to reverse immune suppression as a result of Treg 
function both in vitro and in vivo.65 Ultimately, by 
inducing Treg expansion, the tumor takes advantage 
of the inhibitory function that these cells exert on all 
the immune components. Avoiding the physical elim-
ination of Treg cells would be potentially useful as it 
would prevent the induction of a new wave of periph-
erally converted Treg cells that are endowed with a 
wide TCR repertoire. Conversion would also redirect 
potential effector T cells toward the Treg cell pheno-
type. Alternatively, Treg cell inactivation is a suitable 
strategy, which would functionally impair Treg cell 
suppression  without  changing  the  TCR  repertoire 
of the expanded Treg cell population. Triggering of 
TLR8 or OX40, and potentially blocking adenosine, 
might improve the chances of neutralizing Treg cell 
immunosuppression in cancer immunotherapy.
Myeloid-derived suppressor cells
Myeloid-derived  suppressor  cells  (MDSCs)  are  a 
heterogeneous population of cells that expand dur-
ing­cancer,­inflammation­and­infection,­and­have­a­
remarkable  ability  to  suppress  T-cell  responses.66 
Although suppressive myeloid cells were described 
more than 20 years ago in patients with cancer,67 their 
functional importance in the immune system has only 
recently been appreciated.
Accumulating evidence has now shown that that this 
population of cells contributes to the negative regulation 
of immune responses during cancer and other diseases. 
Common features to all MDSCs are their myeloid origin, 
their immature state and a remarkable ability to suppress 
T-cell responses. In addition to their suppressive effects 
on adaptive immune responses, MDSCs have also been 
reported to regulate innate immune responses by modu-
lating the cytokine production of macrophages.68 More 
recently, it has become clear that the suppressive activ-
ity of MDSCs requires not only factors that promote 
their expansion, but also factors that induce activation. 
The expression of these factors, which are produced 
mainly by activated T cells and tumor stromal cells, is 
induced by different bacterial and viral products, or as a 
result of tumor cell death.69
Macrophages
Macrophages undergo activation in response to envi-
ronmental signals, including microbial products and 
cytokines.70  In  response  to  some  bacterial    moieties 
e.g. lipopolysaccharide LPS) and IFN-γ,   macrophages 
undergo  classic  (M1)  activation.    Alternative  (M2)- 
activated  macrophages  come  in  different  varieties 
depending on the eliciting signals mediated through 
receptors that include IL-4, IL-13, immune   complexes 
plus signals mediated through receptors that involve 
downstream signaling through MyD88, glucocorticoid 
hormones and IL-10. The various forms of M2 activa-
tion are oriented to the promotion of   tissue remodeling 
and  angiogenesis,  parasite  encapsulation,  regulation 
of immune responses as well as   promotion of tumor 
growth. Recent results have highlighted the   integration 
of M2-polarised macrophages with   immunostimulatory 
pathways. They have been shown to induce differen-
tiation of Treg cells71 and   conversely, Tregs have been 
reported  to  induce  alternative  activation  of  human 
mononuclear phagocytes.72   Cancer has thus served as 
a paradigm of in vivo M2 polarization.73
physical Barriers, Tumor stroma  
and Vessels
The tumor environment represents another challenge 
for cancer vaccines. Established epithelial tumors can 
be surrounded by basal-membrane-like   structures which 
prevent­infiltration­by­lymphocytes­and­the­expansion­
of­tumor-specific­T-cells­at­the­tumor­site­and­in­lym-
phoid tissues.74 Solid tumors larger than about 1–2 mm Joseph Murphy
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in diameter require the presence and support of stromal 
cells for blood supply, growth   factors and structural 
support.­The­stroma­consists­of­cancer-associated­fibro-
blasts (CAF), tumor endothelial cells (TEC) and tumor-
associated macrophages (TAM) and can represent more 
than 50% of the tumor tissue depending on the type 
tumor.75 Stromal cells do not only represent a physi-
cal barrier but also release soluble mediators (TGF-β, 
IL-10,   prostaglandin) which inhibit immune responses 
and promote   angiogenesis and tumor progression.76,77 
  Conventional  cancer    treatments,  such  as  de-bulking 
surgery, chemo- or radiotherapy, not only destroy tumor 
cells but also destroy or damage stromal cells that may 
contribute to breaking   immunological resistance and 
  immunosuppression.78 The intricate interplay between 
tumor and stroma attracts their simultaneous immune 
destruction: when highly expressed TAAs on tumor 
cells are cross-presented by stromal cells to T-cells, the 
stromal component also becomes a target of cytotoxic 
T-cell killing.79
TGFβ-1 regulates the production of cytokines and 
growth­factors­by­stromal­and­tumor­cells,­such­as­fibro-
blast growth factor (FGF), connective tissue growth 
factor (CTGF) and vascular endothelial growth fac-
tor (VEGF), which promote angiogenesis and tumor 
progression.45 The new tumor vasculature is generally 
both  structurally  and  functionally    abnormal,  which 
makes­ trafficking/recirculation­ of­ the­ tumor­ ­ tissue­
by lymphocytes and treatments including cancer vac-
cines,­extremely­difficult.­Anti-angiogenic­treatments,­
including immunological targeting of antigens over-
expressed on endothelial cells during angiogenesis or 
antibody  blockade  of  VEGF-receptors  “normalize” 
the tumor vasculature.80,81 This treatment also reverts 
epithelial tumors to non-invasive type and may also 
aid the penetration of vaccines and other treatments 
in the tumor tissue. Moreover, IL-12 inhibits angio-
genesis via an IFN-γ mediated pathway,82 while adop-
tively­transferred­tumor-specific­CD8+ T-cells destroy 
the vasculature of established tumors via an antigen-
independent, IFN-γ-dependent mechanism.83
Mechanisms of Tumor Induced 
Tolerance/escape from the Immune 
system
Despite the evidence that immune effectors play a 
significant­role­in­controlling­role­in­tumor­growth­
under natural conditions or in response to therapeutic 
manipulation, it is well known that malignant cells can 
evade immune surveillance.84 This is due in part to the 
fact­peptides­with­sufficient­immunogenic­­ potential­
are not presented by malignant cells to antigen pre-
senting  cells  under  molecular/cellular    conditions 
conducive to an effective immune response. From a 
Darwinian perspective, the neoplastic tissue can be 
envisaged as a microenvironment that selects for bet-
ter growth and resistance to the immune attack. Can-
cer cells are genetically unstable and can lose their 
antigens by mutation. This instability, combined with 
an immunological pressure, could allow for selective 
growth  of  antigen-loss  mutants.85  Mechanistically 
this could operate at several levels including: loss of 
the  whole  protein  or  changes  in  immunodominant 
T-cell epitopes that alter T-cell recognition, antigen 
  processing or binding to the MHC. Antigen loss has 
been demonstrated in patients with melanoma and 
B-cell  lymphoproliferative  disease.86,87  Moreover, 
many cancer vaccines aim to induce a therapeutic 
CD8+ cytotoxic T-cell response against TAAs. This in 
turn is dependent on correct processing and presenta-
tion of TAAs by MHC class I molecules on tumor 
cells. This pathway is complex and involves multiple 
intracellular components. Defects in the components 
of the MHC class I antigen processing pathway are 
frequently found in human cancers and can occur in 
concert with the loss of tumor antigens.88,89 Other can-
cer  related  mechanisms  underlying  tumor  immune 
escape  include  loss  of  TAA  expression,90  lack  of 
co-stimulatory  molecules  expression,91  inactivating 
mutations of antigen presentation related molecules,92 
production  of  soluble  immunosuppressive  factors 
such as transforming growth factor beta (TGF-beta), 
interlukin-10 (IL-10), reactive oxygen species (ROS), 
nitric oxide (NO), produced by tumor cells.
candidates for Immunotherapy  
in Oncology
Malignant melanoma, renal cancer and prostate   cancer 
are potentially immunogenic, making them good can-
didates for immunotherapeutic approaches.93,94 Mela-
noma has been the most popular target for T-cell-based 
immunotherapy in part as it is much easier to grow 
tumor-reactive T-cells from melanoma patients than 
any other type of human cancer.95 However, many 
promising immune-based therapies have been ineffec-
tive in human clinical trials.96 For example, although Cancer immunotherapy
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IL-2, licensed for use in malignant   melanoma in the 
USA, can induce long-term regression of metastatic 
tumors  it  has  been  associated  with  high  levels  of 
  toxicity.97 As yet, no approved therapy for advanced 
melanoma  has  improved  overall  survival  to  date. 
Other immunotherapies for melanoma have not been 
used outside the setting of clinical trials.
Immunotherapeutic  approaches  currently  under 
investigation for renal cancer include vaccines, which 
have been used with limited success. In a Phase I trial, 
a granulocyte-macrophage colony-stimulating factor 
(GMCSF)-secreting vaccine administered to patients 
with­metastatic­renal­cancer­induced­significant­tumor­
regression in one patient. Additionally, infusion with 
lymphocytes that secrete anti-tumor cytokines, such 
as tumor necrosis factor, has also been used in clini-
cal trials.98
IL-2  is  approved  in  the  USA  for  the  adjuvant 
  therapy  of  stage  III  renal  cancer.99  In  some  cases 
IL-2  has  been  demonstrated  to  induce  long-term 
regression of metastatic tumors and durable complete 
responses of metastatic tumors, probably by induc-
ing T-cell activation. Interferon-α has been used in 
clinical trials and has demonstrated a response rate of 
15%–20% in patients with metastatic disease. Combi-
nation therapy with IL-2 has demonstrated improved 
response rates versus IFN-α alone, although this has 
not been shown consistently.62
combination Immunotherapy
A deeper understanding of the mechanisms   underlying 
the  generation  of  tumor  immunity  has  provided 
a  framework  for  developing  more  potent  immu-
notherapies. A  major  insight  is  that  combinatorial 
approaches that address the multiplicity of defects in 
the host response are likely to be required for clinical 
­ efficacy.100 In addition to surgery, nanotechnology101 
and molecular imaging102 are methods employed with 
cancer  immunotherapy.  The  following  summarizes 
some of the combinations that have been tested in 
laboratory and clinical settings.
Chemotherapy and mAb
Immunostimulatory mAbs directed to immune recep-
tors have emerged as a new and promising strategy 
to­fight­cancer.­In­general,­mAbs­can­be­designed­
to bind molecules on the surface of lymphocytes or 
antigen presenting cells to provide activating   signals 
e.g. CD28, CD137, CD40 and OX40.103 Mabs can also 
be used to block the action of   surface receptors that 
normally down regulate immune responses, cytotoxic 
T-lymphocyte-associated    antigen  4  (CTLA-4)  and 
PD-1/B7-H1. In combined regimes of   immunotherapy, 
these  mAbs  are  expected  to  improve  therapeutic 
  immunizations against tumors as observed in preclini-
cal studies. Anti-4–1BB (agonistic anti-CD137) mAb 
has been successfully tested as an anti-cancer molecule 
in pre-clinical studies.104 Clinical trials of chemother-
apy­and­mAb­have­resulted­in­some­efficacy­against­
cancer in patients.105 For example, tremelimunamab 
induced durable objective responses with low-grade 
toxicities when used as second-line   monotherapy in 
a phase-I study with melanoma patients treated with 
  single, escalating doses.106 Moreover, phase I studies 
of   ipilimumab were performed in patients with pros-
tate, melanoma and ovarian cancer. In these studies, 
patients after a single administration of ipilimumab 
achieved­ some­ clinical­ efficacy­ as­ demonstrated­
by incomplete reduction of tumor size with exten-
sive­ tumor­ necrosis­ with­ leukocyte­ infiltration.­ In­
phase II studies, repeated administrations with ipili-
mumab allowed more patients to achieve objective 
  responses.107  The  combination  of  ipilimumab  with 
chemotherapeutics  (dacarbazine)108  or  docetaxel,109 
with  IL-2110  or  with  melanoma-associated  peptide 
vaccines111 improved the rate of complete responses 
in patients compared with the monotherapy arms.
Chemotherapy and active specific 
immunotherapy
Clinical trials utilizing both chemotherapy and vac-
cine therapy have been performed in patients with 
different cancer types, including glioblastoma multi-
forme (GBM),112 colon cancer,113 pancreatic cancer,114 
prostate cancer115 and small cell lung cancer.116 For 
example, Wheeler et al (2004)112 investigated the   clinical 
responsiveness  of  GBM  to  chemotherapy  after 
  vaccination. Three  groups  of  patients  were  treated 
with chemotherapy alone, vaccination alone or che-
motherapy after vaccination. All patients   subsequently 
underwent a craniotomy and received radiation. The 
vaccination  consisted  of  autologous  dendritic  cells 
loaded  with  either  peptides  from    cultured  tumor 
cells  or  autologous  tumor  lysate.  Results  demon-
strated­ a­ significantly­ longer­ post­ ­ chemotherapy­
survival  in  the  vaccine/chemotherapy  group  when Joseph Murphy
76  Clinical Medicine Insights: Oncology 2010:4
compared with the vaccine and   chemotherapy groups 
in isolation. Overall, data suggests that vaccination 
against­ ­ cancer-specific­ antigens­ can­ sensitize­ the­
tumor  against  subsequent  chemotherapeutic  treat-
ment. Although the mechanisms that underlie such a 
synergistic effect have not yet been elucidated, it is 
speculated that the vaccination-induced increase in 
the frequency of primed T cells constitutes a major 
advantage by the time the tumor microenvironment is 
modified­by­cytotoxic­drugs.
Chemotherapy and adoptive  
lymphocyte immunotherapy
Lymphodepletion by chemotherapy followed by the 
adoptive transfer of lymphocytes has been evaluated 
in small scale studies in melanoma patients.117 In a 
study by Dudley et al 2005,118 35 patients were adop-
tively  transferred  with  autologous  cytotoxic  lym-
phocytes with the administration of IL-2 1 day after 
cyclophosphamide  and  pludarabine  administration. 
They observed a complete response in only 3 patients, 
partial responses in 15 and no response in 17 patients. 
Larger-scale­studies­are­needed­to­assess­the­efficacy­
of this treatment modality in cancer patients.
Humoral Immunotherapy
B-cell activation results in the production of   antibodies 
that can bind to immunogenic cell-surface proteins on 
tumor cells. These initiate complement-mediated cell 
lysis, bridge NK cells or macrophages to the tumor 
for  antibody-dependent  T-cell-mediated  cytotoxic-
ity (ADCC). They in turn interfere with tumor cell 
growth by blocking survival or inducing apoptotic 
signals, or increase immunogenicity by facilitating the 
uptake and presentation of tumor antigens by APCs. 
Thus, enhancing B-cell responses in vivo or provid-
ing a large amount of in vitro—generated­antibodies­
has the potential to promote antitumor activity.
The  widely  used,  rituximab,  binds  CD20  and 
if  given  alone  or  with  chemotherapy,  can  induce 
high  rates  of  remission  in  patients  with  B-cell 
  lymphomas,119 as does cetuximab, which completely 
inhibits  the  binding  of  epidermal  growth  factor 
(EGF).120 Some mAbs can mediate antitumor activ-
ity   independent of effector cells, such as by blocking 
essential survival signals or inducing apoptotic sig-
nals. For example, two mAbs approved for clinical 
use, reactive with the Her-2/Neu receptor on breast 
cancer cells and the   epidermal growth factor receptor 
on­ epithelial­ tumors,­ ­ provide­ therapeutic­ benefits­
in part by blocking growth   signals. The antitumor 
activity of mAbs can also be enhanced by attaching 
radioisotopes or drugs or by engineering recombinant 
bi-specific­antibodies­that­simultaneously­bind­tumor­
cells and activate receptors on immune effector cells 
such as CD3 or FcR.121
The­efficacy­of­stimulating­a­patient’s­own­tumor-
reactive B-cells may be limited by the magnitude of the 
antibody response that can be achieved in vivo. Nev-
ertheless, this approach remains appealing because of 
demonstrations with tumor cell expression libraries 
that sera from a large fraction of patients already con-
tain tumor-reactive antibodies. The simplest means 
to stimulate such B-cells in vivo is to provide tumor 
antigens in immunogenic vaccine formulations, such 
as mixed with adjuvants or conjugated to antigens 
that can elicit helper T-cell responses. Marked clini-
cal results have been observed after priming patients 
with autologous dendritic cells (discussed previously). 
These  cells  were  pulsed  with  the  unique  idiotypic 
immunoglobulin derived from the B-cell receptor of 
a patient’s own B-cell lymphoma followed by boost-
ing with the immunoglobulin conjugated to the helper 
protein keyhole limpet hemocyanin (KLH).
Alternative approaches for activating and expand-
ing  existing  B-cell  responses  in  vivo  by  ligation 
of  co-stimulatory  molecules,  such  as  CD40  or  by 
administration  of  the  B-cell  proliferative  cytokine 
IL-4 have not met with much success in preclinical 
models and could potentially induce hazardous auto-
reactive antibodies. Thus, humoral therapy will likely 
continue to be dominated by passive administration 
of­mAbs­­ specific­for­selected­tumor­antigens.
conclusion
Immunotherapy  may  be  the  next  great  hope  for 
  cancer  treatment.  While  monoclonal  antibodies, 
cytokines, and vaccines have individually shown 
some  promise,  it  is  likely  that  the  best  strategy 
to combat cancer will be to attack on all fronts. 
Clearly, different strategies demonstrate benefit in 
different patient populations. It may be that the best 
results are obtained with   vaccines in combination 
with a variety of antigens, or vaccine and antibody 
combinations. A   nonspecific and   specific immuno-
therapy combination offers another potent strategy. Cancer immunotherapy
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The effect of any of the   aforementioned strategies 
in combination with more   traditional cancer thera-
pies is another promising avenue. Using these con-
certed efforts, the ultimate achievable goal may be 
a durable anti-tumor immune response that can be 
maintained over the course of a patient’s lifespan.
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